文章预览
According to the World Health Organization (WHO), 38% of China’s population was overweight and 8% was obese in 2022. While the obesity rate is much lower than in many Western countries including the United States, the growth rate is outpacing its eastern neighbors South Korea, Japan, and Singapore. This has not only captured the attention of authorities, but netizens as well. It has lead to the rise of commercial weight loss camps and buzz around Ozempic, the most famous weight loss drug in the GLP-1 category. The recent approval of GLP-1 drugs like Ozempic in China marks a significant shift in the country’s regulatory stance toward weight-management medications. However, challenges remain. Patients are concerned over side effects and high costs, amid mixed reactions on social media. GLP-1 drugs and their applications in weight control Ozempic is becoming widely embraced in the West, with celebrities endorsements from Hollywood stars like Amy Schumer and tech billionaire El
………………………………
